Alpine Immune Sciences Overview
- Founded
- 2014
- Status
- Public
- Employees
- 57
- Stock Symbol
- ALPN
- Investments
- 1
- Share Price
- $6.98
- (As of Monday Closing)
Alpine Immune Sciences General Information
Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.
Contact Information
- 188 East Blaine Street
- Suite 200
- Seattle, WA 98102
- United States
Alpine Immune Sciences Timeline
Alpine Immune Sciences Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$6.98 | $7.66 | $6.00 - $15.14 | $224M | 29.2M | 133K | -$1.72 |
Alpine Immune Sciences Financials Summary
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
---|---|---|---|---|
EV | 242,951 | 181,110 | 41,025 | (6,340) |
Revenue | 24,556 | 9,335 | 1,740 | 705 |
EBITDA | (40,012) | (26,838) | (42,294) | (37,442) |
Net Income | (41,508) | (27,940) | (41,852) | (36,487) |
Total Assets | 233,480 | 144,090 | 54,093 | 54,873 |
Total Debt | 21,102 | 22,598 | 16,356 | 4,203 |
Alpine Immune Sciences Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Alpine Immune Sciences‘s full profile, request access.
Request a free trialAlpine Immune Sciences Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Alpine Immune Sciences‘s full profile, request access.
Request a free trialAlpine Immune Sciences Comparisons
Industry
00000000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAlpine Immune Sciences Competitors (5)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Zymeworks | Formerly VC-backed | Vancouver, Canada | 000 | 00000 | 000000 - 000 | 00000 |
000000000 00000000 | Formerly VC-backed | Tarrytown, NY | 00000 | 00000 | 00000000000 | 00000 |
00000000000 | Formerly VC-backed | Rockville, MD | 000 | 00000 | 000000000 | 00000 |
00000000 0000 | Formerly VC-backed | Austin, TX | 00 | 00000 | 00000000 | 00000 |
000000 | Formerly VC-backed | Monrovia, CA | 000 | 00000 | 00000000 | 00000 |
Alpine Immune Sciences Patents
Alpine Immune Sciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210363223-A1 | April and baff inhibitory immunomodulatory proteins and methods of use thereof | Pending | 08-May-2020 | 000000000000 | |
CA-3136816-A1 | Methods and uses of variant icos ligand (icosl) fusion proteins | Pending | 17-Apr-2019 | 00000000000 | |
AU-2019389151-A1 | Cd86 variant immunomodulatory proteins and uses thereof | Pending | 30-Nov-2018 | 000000000000 | |
CA-3120868-A1 | Cd86 variant immunomodulatory proteins and uses thereof | Pending | 30-Nov-2018 | 000000000000 | |
EP-3887394-A2 | Cd86 variant immunomodulatory proteins and uses thereof | Pending | 30-Nov-2018 | C07K14/70532 |
Alpine Immune Sciences Executive Team (10)
Alpine Immune Sciences Board Members (10)
Name | Representing | Role | Since |
---|---|---|---|
Christopher Peetz | Self | Board Member | 000 0000 |
James Topper Ph.D | Self | Board Member | 000 0000 |
Jay Venkatesan MD | Self | Board Member | 000 0000 |
Mitchell Gold MD | Alpine Immune Sciences | Chief Executive Officer & Chairman | 000 0000 |
Natasha Hernday | Self | Board Member | 000 0000 |
Alpine Immune Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAlpine Immune Sciences Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Alpine Immune Sciences‘s full profile, request access.
Request a free trialAlpine Immune Sciences Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 00000 | 24-Jul-2017 | 0000000000 | 0000 | Biotechnology | 00000000 |